European Journal of Biomedical and Pharmaceutical Sciences

THE RETICULOCYTE IN SICKLE CELL ANEMIA: BIOMARKER TOTHERAPEUTIC TARGET

Atul Desai (BAMS, FIIM, PhD)*, Dr. Kavita Desai (BAMS, PGDHHM), Jayesh C. Shah (M.SC (Micro)) and Dr. Danish Javed

ABSTRACT

Sickle Cell Anemia (SCA) is a hereditary hemoglobinopathy characterized by chronic hemolytic anemia and recurrent vaso-occlusive crises (VOCs). Reticulocytes—immature red blood cells—are increasingly recognized not only as markers of bone marrow activity but also as active contributors to SCA pathophysiology. This study reviews the dual role of reticulocytes in disease progression, emphasizing their adhesive properties mediated by surface molecules such as CD36, CD71, and α4β1 integrin, which facilitate endothelial interactions and vascular occlusion. Elevated absolute reticulocyte counts (ARC), particularly in early infancy, correlate with increased risks of stroke, VOCs, and mortality, offering predictive value for clinical outcomes. Therapeutic strategies, including hydroxyurea, crizanlizumab, L-glutamine, and the herbo-mineral formulation T-AYU-HM Premium, show promise in reducing reticulocyte adhesion and improving patient outcomes. Integrating reticulocyte profiling into clinical practice enables early risk stratification and paves the way for personalized interventions. Targeting reticulocyte adhesion represents a promising avenue for reducing disease burden and enhancing the quality of life in SCA patients.

Keywords: Sickle Cell Anemia; Reticulocytes; Absolute Reticulocyte Count (ARC); Medium Fluorescence Reticulocytes (MFR); Vaso-Occlusive Crisis (VOC); Stroke Risk; Adhesion Molecules; CD36; CD71; ?4?1 Integrin; Hydroxyurea; Crizanlizumab; L-Glutamine; T-AYU-HM Premi